International Scholarly Research Notices / 2012 / Article / Tab 1

Research Article

How Far Do the Complaints of Patients with Parkinson’s Disease Reflect Motor Fluctuation? Quantitative Analysis Using a Portable Gait Rhythmogram

Table 1

Clinical features of patients with Parkinson’s disease.

Case no.Age (years)GenderDuration (years)M H-YUPDRS Part IIIMedication
Total scoreGaitPostural stabilityBradykinesia

Subjective good

173M3.6 312122L-dopa 300 mg, Ama 200 mg
273M3.6 312122L-dopa 300 mg, Ama 200 mg
379M1.3 344222L-dopa 300 mg
470F2.8 311121L-dopa 300 mg, Pra 1.5 mg
555M2.5 211000Rop 4 mg, Ama 200 mg
670F3.6 2.59111L-dopa 300 mg
775M3.0 323122None
864F2.6 316211Rop 2 mg, Ama 200 mg
973F7.7 1.510000L-dopa 300 mg, Pra 3 mg, Ama 100 mg
1083M3.7 212201Ama 100 mg
1163F0.5 223101None
1276M3.1 216000L-dopa 300 mg
1379M3.5 334122L-dopa 300 mg
1479M3.5 2.529112L-dopa 200 mg, Tri 4 mg
1578M8.3 211000None
1679M3.8 323121L-dopa 300 mg, Pra 1.5 mg
1778M2.9 2.514111L-dopa 300 mg
1875F2.4 335222L-dopa 300 mg, Pra 1.0 mg
1977M17.6 330213Pra 2.0 mg, Ama 100 mg
2075M11.7 326122L-dopa 300 mg
2164M1.8 1.510011L-dopa 300 mg, Pra 1.5 mg
2263F1.3 221001None
2363F1.4 219001Pra 2 mg

Subjective not good

2476M17.3 336223Ama 100 mg
2567M3.3 230111L-dopa 300 mg, Ama 200 mg
2671M3.4 329111L-dopa 300 mg, Rop 4 mg
2769M1.0 317122None
2859M9.0 215001L-dopa 300 mg, Pra 3 mg, Sel 5 mg, Ama 200 mg
2977M2.8 2.521111L-dopa 400 mg
3082M3.9 431212L-dopa 300 mg, Rop 3 mg
3164M1.5 1.58001L-dopa 300 mg
3279M7.7 321211L-dopa 400 mg, Per 1.25 mg, Sel 5 mg
3378F2.0 331123None
3481F8.2 317122L-dopa 300 mg, Rop 2 mg
3565F3.3 2.519122Pra 1 mg, Ama 200 mg
3677F9.6 2.523111L-dopa 300 mg, Rop 2 mg
3756F2.3 318122L-dopa 300 mg, Rop 9 mg, Ama 200 mg
3873F0.5 311021None
3974F2.3 335222L-dopa 300 mg
4070F2.8 314121L-dopa 300 mg
4166F2.7 2.515111L-dopa 200 mg, Rop 6 mg
4272M8.3 324111L-dopa 400 mg, Rop 5 mg
4365M1.7 1.510100Tri 4 mg
4464F12.8 3.521121L-dopa 500 mg, Pra 4 mg, Ent 500 mg

M H-Y: modified Hoehn and Yahr stage, UPDRS: unified Parkinson's disease rating scale, gait: “gait” score, postural stability: “postural stability” score, bradykinesia: “body bradykinesia and hypokinesia” score, Ama: amantadine, Pra: pramipexole, Rop: ropinirole, Tri: trihexyphenidyl, Sel: selegiline, Ent: entacapone, subjective good: patients who did not notice wearing off, and subjective wearing off: patients who noticed subjectively wearing off.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.